

Figures

Figure 1 (Analysis 2.1)






Figure 2 (Analysis 2.2)



Therapeutic anticoagulants versus Prophylactic anticoagulants for VTE prophylaxis...


05-Sep-2022

Figure 3 (Analysis 2.3)




Forest plot of comparison: 2 Therapeutisk vs. anden dosis (kritisk covid-19), outcome: 2.3 Major bleed.

Figure 4 (Analysis 3.1)



Forest plot of comparison: 3 Intermediaer vs.profilaktisk dosis (kritisk covid-19), outcome: 3.1 All-cause death

Figure 5 (Analysis 3.2)



Forest plot of comparison: 3 Intermediaer vs.profilaktisk dosis (kritisk covid-19), outcome: 3.2 Clotting Event

Therapeutic anticoagulants versus Prophylactic anticoagulants for VTE prophylaxis...

05-Sep-2022

Figure 6 (Analysis 3.3)

Study or Subgroup		Intermediär dosis Events	Total Events	Prophylaktisk dosis Events	Total Events	Weight	M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
INSPIRATION 2021	7	276	4	286	71,7%	1.81 [0,54, 6,13]		
Perepu 2021	2	87	2	86	28,3%	0,99 [0,14, 6,86]		
Total (95% CI)	363		6	372	100,0%	1,53 [0,54, 4,28]		
Total events	9		6					
Heterogeneity: $\tau^2 = 0.00$; Chi $^2 = 0.27$, df = 1 ($P = 0.60$); $I^2 = 0\%$								
Test for overall effect: $Z = 0.81$ ($P = 0.42$)								

Forest plot of comparison: 3 Intermediär vs.prophylaktisk dosis (kritisk covid-19), outcome: 3.3 Major Bleeding.

Figure 7 (Analysis 5.1)

Study or Subgroup		Terapeutisk Events	Total Events	Anden dosis Events	Total Events	Weight	M-H, Random, 95% CI	Risk Ratio M-H, Random, 95% CI
5.1.1 Therapeutic vs. prophylactic								
Marcos-Jubilar (BEMCOP) 2022	2	32	1	33	31 %	2,06 [0,20, 21,64]		
Munoz-Rivas (PROTHROMCOVID) 2022	3	103	2	106	5,3%	1,54 [0,26, 9,05]		
Sholzberg (RAPID) 2021	4	228	18	237	12,6%	0,23 [0,08, 0,67]		
Subtotal (95% CI)	363		376		21,0%	0,72 [0,16, 3,29]		
Total events	9		21					
Heterogeneity: $\tau^2 = 1.08$; Chi $^2 = 6$, $df = 2$ ($P = 0.08$); $I^2 = 60\%$								
Test for overall effect: $Z = 0.43$ ($P = 0.67$)								

5.1.2 Therapeutic vs. prophylactic/intermediate dosis

REMAP-CAPACITV-4aATTAC/C #2 2021	86	1180	86	1046	45,1%	0,89 [0,67, 1,18]		
Syropoulos (IEP-COVID) 2021	25	129	31	124	33,9%	0,78 [0,49, 1,23]		
Subtotal (95% CI)	1309		1170		79,0%	0,85 [0,67, 1,99]		
Total events	111		117					
Heterogeneity: $\tau^2 = 0.00$; Chi $^2 = 0.23$, $df = 1$ ($P = 0.63$); $I^2 = 0\%$								
Test for overall effect: $Z = 1.26$ ($P = 0.21$)								

Forest plot of comparison: 5 Therapeutic vs. anden dosis (moderat/avtorlig covid-19), outcome: 5.1 All-cause death.

Figure 8 (Analysis 5.2)



Therapeutic anticoagulants versus Prophylactic anticoagulants for VTE prophylaxis...

05-Sep-2022





Figure 9 (Analysis 5.3)



Review Manager 5.4.1

Therapeutic anticoagulants versus Prophylactic anticoagulants for VTE prophylaxis...


05-Sep-2022

Figure 10 (Analysis 7.1)




Forest plot of comparison: 7 | Intermediaär vs.protylaktisk| dosis (moderat/alvorlig covid-19), outcome: 7.1 All-cause death.

Figure 11 (Analysis 7.2)



Forest plot of comparison: 7 | Intermediaär vs.protylaktisk| dosis (moderat/alvorlig covid-19), outcome: 7.2 Clotting event.

Figure 12 (Analysis 7.3)



Forest plot of comparison: 7 | Intermediaär vs.protylaktisk| dosis (moderat/alvorlig covid-19), outcome: 7.3 Major bleeding.

Figure 13

	Random sequence generation (selection bias)	All location concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessors (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Blondon (Swiss COVID-HEP) 2022	+	+	+	+	+	+	+
INSPIRATION 2021	+	?	+	+	+	+	+
Lawler 2021	+	?	+	+	+	+	+
Lemos (HESACOVID) 2020	+	?	+	+	+	+	+
Lopes (ACTION) 2021	+	?	?	?	+	+	+
Marcos-Jubilar (BEMCOP) 2022	+	+	?	?	+	+	+
Monti (x-COVID) 2021	+	+	?	?	+	+	+
Muñoz-Rivas (PROTHROMCOVID) 2022	+	+	?	?	+	+	+
Olymik 2021	+	+	?	?	?	?	?
Perepu 2021	+	+	?	?	+	+	+
REMAP-CAP/ACTIV-4a/ATTACC #1 2021	+	+	?	?	+	+	+
REMAP-CAP/ACTIV-4a/ATTACC #2 2021	+	+	?	?	+	+	+
Sholzberg (RAPID) 2021	+	+	?	?	+	+	+
Spiropoulos (HEP-COVID) 2021 (NCT04401293)	+	+	+	+	+	+	+
Spiropoulos 2021 (HEP-COVID) 2021	+	+	+	+	+	+	+
Zarychanski 2021							

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.